Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681 | Vol. 03, Issue-03, March-2026 | pp.-32-45

ORIGINALARTICLE https://aktpublication.com/index.php/jprims/index

Biopharmaceutics Meets Neuropharmacology: Advanced Systems for Brain-Targeted Drug Delivery

Neha Mandle[1], Devendra Kumar Sahu[2], Tarun Kumar Jain[3], Harsh Kumar Tamrakar[4], Chiranjeev Sahu[5*]

[1]Shri Shankaracharya College of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, 490020.
[2]Faculty of Pharmacy, Kalinga University, Telibandha, Raipur, Chhattisgarh, 492001.
[3]Shri Balaji College of Pharmaceutical Sciences, Sakti, Chhattisgarh, 495689.
[4]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, 490020.
[5]Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Bhilai, 490023.
***Corresponding Email: chiranjeevsahu2001@gmail.com**

Abstract:

Brain-targeted drug delivery represents one of the most challenging frontiers in pharmacology due to the presence of the blood–brain barrier (BBB), enzymatic degradation, and efflux transporters. Integration of biopharmaceutics with neuropharmacology has enabled the design of advanced delivery systems that enhance drug bioavailability, specificity, and therapeutic efficacy in central nervous system (CNS) disorders. This review explores current strategies for brain-targeted delivery, including nanoparticles, liposomes, polymeric carriers, and ligand-mediated systems. Mechanistic insights into BBB penetration, pharmacokinetic considerations, and clinical translation challenges are discussed. Future directions involve stimuli-responsive carriers, nanotheranostics, and precision neuropharmacology for personalized CNS therapy.

Keywords: Brain-targeted delivery, blood–brain barrier, nanoparticles, neuropharmacology, biopharmaceutics, CNS disorders, ligand-mediated targeting.

Received: Dec. 22, 2025 **Revised: Jan. 27, 2026** **Accepted: Feb. 21, 2026** **Published: March. 19, 2026**

DOI: https://doi.org/10.64063/3049-1681.vol.3.issue3.3

https://aktpublication.com/index.php/jprims/issue/archive

1. Introduction

Delivering therapeutics to the central nervous system (CNS) remains a significant challenge in modern pharmacology due to the presence of multiple physiological barriers. Chief among these is the blood–brain barrier (BBB), a highly selective interface formed by tight junctions between

endothelial cells, active transport mechanisms, and enzymatic activity [1]. While the BBB protects the CNS from harmful substances, it also restricts the entry of many potentially therapeutic compounds, limiting their clinical effectiveness. In addition, drug metabolism and efflux mechanisms, including the action of P-glycoprotein and other transporters, further reduce the bioavailability of drugs within the CNS, preventing adequate therapeutic concentrations from being achieved through conventional systemic administration [2]. As a result, traditional pharmacological approaches often fail to deliver sufficient drug levels to the brain without inducing systemic toxicity, highlighting the need for more advanced strategies.

To overcome these challenges, modern biopharmaceutic strategies integrate principles from neuropharmacology and pharmaceutical sciences. Understanding CNS targets, receptor pharmacodynamics, and disease-specific pathways is critical for designing drugs with optimal efficacy [3-4]. Concurrently, biopharmaceutics focuses on optimizing drug absorption, distribution, metabolism, and controlled-release properties to maximize CNS exposure while minimizing off-target effects. By combining these approaches, researchers aim to develop therapeutic formulations that can efficiently penetrate the BBB, maintain effective CNS concentrations, and reduce systemic side effects, thereby enhancing the safety and efficacy of treatments for neurological disorders [5].

2. Blood–Brain Barrier and Drug Delivery Challenges

The blood–brain barrier (BBB) is a dynamic and highly selective interface that regulates the entry of substances from the systemic circulation into the central nervous system (CNS) [6]. Structurally, the BBB is composed of endothelial cells connected by tight junctions, which severely restrict paracellular transport and prevent passive diffusion of most hydrophilic molecules. In addition to this physical barrier, the BBB employs efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which actively pump xenobiotics and drugs back into the bloodstream, further limiting intracellular accumulation [7-8]. The barrier is also fortified by enzymatic metabolism**,** primarily through cytochrome P450 (CYP) enzymes and other metabolizing systems, which can degrade or inactivate drugs before they reach therapeutic concentrations in the CNS. Collectively, these structural and functional features pose major obstacles for delivering effective therapeutics to the brain, often necessitating high systemic doses that increase the risk of peripheral toxicity [9-10].

To address these challenges, several innovative strategies have been developed to enhance drug penetration across the BBB. Lipophilic prodrugs are designed to increase passive diffusion into the brain by temporarily modifying polar functional groups, which are then enzymatically cleaved once inside the CNS to release the active drug [11-12]. Another approach leverages receptor-mediated transcytosis**,** in which drugs or carriers are conjugated to ligands for endogenous receptors such as transferrin, insulin, or low-density lipoprotein (LDL) receptors, facilitating their transport across endothelial cells. Additionally, adsorptive-mediated transcytosis utilizes cationic carriers that interact electrostatically with the negatively charged endothelial membrane, enabling enhanced uptake into the CNS [13-14]. These strategies, often combined with advanced formulation technologies such as nanoparticles and liposomes, are

critical for overcoming the restrictive properties of the BBB and improving the therapeutic efficacy of CNS-targeted drugs.

3. Advanced Brain-Targeted Delivery Systems

Recent advances in nanotechnology have opened new avenues for brain-targeted drug delivery, enabling therapeutics to cross the blood–brain barrier (BBB) more efficiently while minimizing systemic side effects [15]. Among these, nanoparticles have emerged as versatile carriers. Polymeric nanoparticles are biodegradable and can be engineered with surface modifications for ligand-mediated targeting of specific CNS receptors, improving specificity and uptake. Lipid nanoparticles offer high encapsulation efficiency and excellent biocompatibility, making them suitable for delivering both hydrophobic and hydrophilic drugs. Additionally, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) combine the advantages of lipid-based systems with enhanced stability and controlled-release properties, providing sustained drug delivery to the brain [26-27].

Liposomes are another widely studied class of brain-targeted carriers. These vesicular systems can be PEGylated to prolong systemic circulation and reduce immune clearance. Moreover, ligand-functionalized liposomes can exploit receptor-mediated transcytosis across the BBB, significantly improving CNS uptake [28-29]. Beyond liposomes, dendrimers represent highly branched, multifunctional nanostructures that can simultaneously deliver drugs, nucleic acids, or imaging agents, offering exceptional precision for CNS-targeted therapy. Their structural versatility allows for the co-delivery of multiple therapeutic modalities within a single platform, which is particularly valuable for complex neurological disorders [30-31].

In addition to synthetic nanocarriers, exosomes—endogenous extracellular vesicles—have gained attention for their natural CNS tropism and ability to transport bioactive molecules across the BBB. With low immunogenicity and inherent cellular communication capabilities, exosomes hold significant potential for personalized therapy, including gene delivery and regenerative applications [32-33]. Together, these advanced delivery systems, whether synthetic or biologically derived, provide a diverse toolkit for overcoming the restrictive nature of the BBB and improving therapeutic outcomes for a variety of neurological disorders [34].Table 1

Table 1. Comparison of Brain-Targeted Delivery Systems

Delivery System	BBB Penetration	Drug Loading	Targeting Potential	Clinical Status	Reference
Polymeric NP	Moderate	High	Ligand modification	Preclinical/Clinical	35
Liposomes	Moderate	Moderate	PEGylation + ligands	Clinical trials	36

Solid Lipid NP	Moderate	High	Surface functionalization	Preclinical	37
Dendrimers	High	Moderate	Multi-ligand attachment	Preclinical	38
Exosomes	High	Moderate	Endogenous targeting	Preclinical	39

4. Mechanisms of CNS Targeting

Effective drug delivery to the central nervous system (CNS) requires overcoming the restrictive nature of the blood–brain barrier (BBB), and contemporary strategies employ a combination of passive, active, and stimuli-responsive targeting mechanisms [40]**.** Passive targeting takes advantage of pathological changes in the BBB that occur in certain disease states, such as tumors, neuroinflammation, or ischemia. In these conditions, the BBB becomes partially disrupted, allowing nanocarriers and small molecules to penetrate the CNS more easily. This approach is particularly relevant for delivering chemotherapeutics to brain tumors, where the enhanced permeability and retention (EPR) effect facilitates selective accumulation of carriers in affected regions [41-42].

Active targeting involves the use of ligand-receptor interactions to guide therapeutic carriers across the BBB with high specificity. By conjugating drugs or nanoparticles with ligands that bind to receptors expressed on the endothelial surface—such as transferrin, insulin, or low-density lipoprotein (LDL) receptors—these systems can engage receptor-mediated transcytosis**,** enabling more efficient and directed transport into the CNS [43]. Active targeting not only improves delivery efficiency but also reduces off-target effects, enhancing the safety profile of CNS therapeutics.

Stimuli-responsive systems represent a further refinement of CNS-targeted delivery. These carriers are engineered to release their therapeutic payload in response to specific physiological triggers present in the CNS microenvironment, such as variations in pH, redox potential, or enzymatic activity [45-46]. Table 2 For example, acidic or oxidative conditions in diseased brain tissue can trigger drug release specifically at the site of pathology, minimizing systemic exposure and maximizing local efficacy. By combining these targeting mechanisms, researchers are developing smart delivery systems that navigate the complex CNS environment, overcome the protective barriers of the brain, and provide precise, controlled therapeutic interventions [47.] (Figure 1)

Figure 1. Mechanisms of Brain-Targeted Drug Delivery



Table 2. Biopharmaceutic Parameters Influencing Brain Delivery

Parameter	Influence on CNS Delivery	Optimization Strategy	Reference
Particle size	<200 nm favors BBB crossing	Controlled formulation	48
Surface charge	Slightly positive enhances uptake	Cationic modification	49
Lipophilicity	Facilitates passive diffusion	Prodrug or lipid conjugation	50
Ligand density	Enhances receptor-mediated transport	Surface functionalization	51

5. Pharmacokinetic and Biopharmaceutic Considerations

Understanding the pharmacokinetic and biopharmaceutic behavior of CNS-targeted therapies is essential for designing effective delivery strategies. A major challenge in CNS drug delivery lies

in achieving efficient absorption while bypassing systemic barriers [52]. Among the most promising approaches is nasal-to-brain delivery**,** which provides direct access to the CNS through the olfactory and trigeminal nerve pathways**,** effectively circumventing the blood–brain barrier. This non-invasive route not only enhances drug bioavailability in the brain but also minimizes first-pass metabolism and systemic exposure, thereby improving the therapeutic index [53-54].

Once administered, distribution of therapeutics within the CNS is largely dictated by the physicochemical properties of the carrier**,** including surface chemistry, size, and charge. Nanocarriers with hydrophilic coatings (e.g., PEGylation) can prolong circulation time and facilitate deeper penetration into the brain parenchyma, while optimal nanoparticle size enhances permeability and retention in targeted regions. Metabolism is another critical consideration—many drugs undergo rapid degradation by enzymatic systems before reaching their target. Encapsulation within nanoparticles, liposomes, or dendrimers offers protection from enzymatic degradation, ensuring that a higher fraction of the drug reaches its intended site of action in active form [55-56].

Finally, elimination pathways determine how long a therapeutic remains active in the CNS. Drugs and nanocarriers are typically cleared through the cerebrospinal fluid (CSF) and systemic circulation, influenced by molecular weight, solubility, and biodegradability [57-58]. Controlled-release formulations and surface modifications can prolong retention time, allowing for sustained therapeutic effects and reduced dosing frequency. By carefully engineering absorption, distribution, metabolism, and elimination (ADME) parameters, modern CNS-targeted delivery systems can achieve more predictable and efficient pharmacokinetic profiles, ultimately enhancing clinical outcomes [59-60].

6. Clinical Applications

The development of advanced brain-targeted drug delivery systems has opened up promising therapeutic avenues across a wide range of neurological disorders. One of the most significant areas of application is in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease [61-62]. These conditions involve complex pathological mechanisms, including the accumulation of amyloid plaques, misfolded α-synuclein, and mutant huntingtin proteins. Targeted nanocarrier systems are being designed to deliver therapeutic molecules that can either inhibit aggregation, promote clearance, or modulate downstream signaling pathways, thereby slowing disease progression and improving cognitive and motor functions [63-64].

CNS tumors, particularly aggressive malignancies like glioblastoma, represent another major therapeutic challenge due to their infiltrative nature and the protective effect of the blood–brain barrier. Ligand-targeted nanoparticles, capable of selectively binding to overexpressed receptors on tumor cells, offer a strategy to enhance drug accumulation in the tumor microenvironment while minimizing systemic toxicity [65-66].

CNS infections, including viral and bacterial conditions such as meningitis and encephalitis, also benefit from these delivery strategies. Liposomal and nanoparticle formulations enable high local drug concentrations in the brain, improving therapeutic efficacy and potentially reducing the duration of treatment [67].

Finally, advanced delivery systems have shown promise in pain management. By enabling controlled and localized CNS delivery of opioids and other analgesics, these systems can reduce systemic exposure and minimize adverse effects such as respiratory depression and dependence. Together, these clinical applications underscore the transformative potential of targeted CNS drug delivery systems in improving therapeutic outcomes across diverse neurological conditions [68-69].

Table 3. Representative CNS-Targeted Therapeutics under Investigation

Disease	Drug	Delivery System	Targeting Strategy	Clinical Stage	Reference
Alzheimer's	Rivastigmine	Liposomes	Receptor-mediated	Preclinical	70
Glioblastoma	Temozolomide	Polymeric NP	Ligand-targeted	Phase I/II	71
Parkinson's	Dopamine	LNP	PEGylated + ligand	Preclinical	72
CNS Infection	Acyclovir	Solid Lipid NP	Intranasal	Preclinical	73

7. Challenges and Future Directions

Despite remarkable progress in brain-targeted drug delivery, several critical challenges continue to limit the full clinical translation of these advanced systems. One of the major hurdles is the limited penetration of therapeutic agents across the blood–brain barrier, which remains highly selective and varies significantly among patients due to factors such as age, disease state, and genetic background [74]. This heterogeneity complicates dose optimization and therapeutic predictability. Another key concern is the potential immunogenicity of nanocarriers, which can trigger unwanted immune responses or rapid clearance from circulation, thereby reducing their therapeutic efficacy. Long-term toxicity and the difficulty of predicting how these carriers will behave in the brain over extended periods further add to safety concerns. Additionally, scaling up production and ensuring reproducibility while maintaining the physicochemical integrity of complex nanocarriers pose significant manufacturing challenges for clinical application [75-76].

In response to these obstacles, several emerging innovations are shaping the future of CNS drug delivery. Stimuli-responsive carriers are being developed to achieve precise spatiotemporal

control of drug release, responding intelligently to physiological triggers within the brain microenvironment [77]. Nanotheranostic systems, which combine therapeutic and imaging functions in a single platform, enable real-time monitoring of drug distribution and treatment response, paving the way for more adaptive and personalized treatment strategies. The concept of personalized neuropharmacology is gaining traction, where drug delivery systems are tailored based on individual genetic, phenotypic, and metabolic profiles to enhance efficacy and minimize adverse effects [78-79]. Furthermore, artificial intelligence is increasingly being integrated into formulation design, helping optimize critical parameters such as particle size, surface chemistry, and ligand density with greater precision and efficiency. These innovations, while still evolving, hold the potential to address many of the current limitations and transform the landscape of CNS-targeted therapies in the near future [80]. (Figure 2)

Figure 2. Future Directions in Brain-Targeted Nanomedicine



8. Conclusion

The integration of biopharmaceutics with neuropharmacology has fundamentally reshaped the landscape of brain-targeted drug delivery. By combining a deep understanding of CNS physiology with advanced formulation science, researchers have developed innovative strategies to enhance therapeutic efficacy and overcome traditional barriers such as the blood–brain barrier. Novel carrier systems, including liposomes, nanoparticles, dendrimers, and exosomes, have shown remarkable potential in improving drug bioavailability in the brain while simultaneously reducing systemic toxicity and off-target effects. These platforms enable more precise delivery, controlled release, and better targeting of disease-specific pathways, ultimately paving the way for more effective treatments.

However, several challenges remain. Limited and variable BBB penetration, potential immunogenicity of carriers, concerns related to long-term safety, and difficulties in large-scale manufacturing continue to hinder seamless clinical translation. Despite these obstacles, the future of CNS drug delivery appears highly promising. Emerging strategies such as stimuli-responsive nanocarriers, ligand-mediated transport systems, nanotheranostics, and personalized

nanomedicine are setting the stage for a new era of precision neurotherapeutics**.** By leveraging these technologies in tandem with advances in artificial intelligence and patient-specific profiling, brain-targeted drug delivery is poised to move from experimental innovation to mainstream clinical reality.

References

1. Dong, X. (2018). Current strategies for brain drug delivery. *Theranostics, 8*(6), 1481–1493.
2. Begley, D. J. (2004). Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. *Pharmacology & Therapeutics, 104*(1), 29–45.
3. Sharma, U., Badyal, P. N., & Gupta, S. (2015). Polymeric nanoparticles drug delivery to brain: A review. *International Journal of Pharmacology, 2*(2), 60–69.
4. Pehlivan, S. B. (2013). Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. *Pharmaceutical Research, 30*(10), 2499–2511.
5. Van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015). Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. *Drug Resistance Updates, 19*, 1–12.
6. Komarova, Y. A., Kruse, K., Mehta, D., & Malik, A. B. (2017). Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability. *Circulation Research, 120*(1), 179–206.
7. Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V., Borm, P., Estrada, G., Ntziachristos, V., & Razansky, D. (2010). Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging. *Particle and Fibre Toxicology, 7*, 3.
8. Bodor, N., & Buchwald, P. (2003). Brain-targeted drug delivery. *American Journal of Drug Delivery, 1*(1), 13–26.
9. Levin, V. A. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. *Journal of Medicinal Chemistry, 23*(6), 682–684.
10. Begley, D. J., & Brightman, M. W. (2003). Structural and functional aspects of the blood-brain barrier. In L. Prokai & K. Prokai-Tatrai (Eds.), *Peptide Transport and Delivery into the Central Nervous System* (pp. 39–48). Birkhäuser.
11. Bawa, R. (2010). Nanopharmaceuticals: Nanopharmaceuticals. *European Journal of Nanomedicine, 3*(1), 34–40.
12. Weissig, V., Pettinger, T. K., & Murdock, N. (2014). Nanopharmaceuticals (Part 1): Products on the market. *International Journal of Nanomedicine, 9*, 4357–4373.
13. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews, 23*(1–3), 3–25.

14. Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014). Current approaches to enhance CNS delivery of drugs across the brain barriers. *International Journal of Nanomedicine, 9*, 2241–2257.
15. Jain, K. K. (2012). Nanobiotechnology-based strategies for crossing the blood-brain barrier. *Nanomedicine, 7*(8), 1225–1233.
16. Wolburg, H., & Lippoldt, A. (2002). Tight junctions of the blood-brain barrier: Development, composition and regulation. *Vascular Pharmacology, 38*(6), 323–337.
17. Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release, 235*, 34–47.
18. Micheli, M.-R., Bova, R., Magini, A., Polidoro, M., Emiliani, C., & De Angelis, M. (2012). Lipid-based nanocarriers for CNS-targeted drug delivery. *Recent Patents on CNS Drug Discovery, 7*(2), 71–86.
19. Rip, J., Schenk, G. J., & de Boer, A. G. (2014). Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood–brain barrier in rats. *Journal of Drug Targeting, 22*(6), 460–467.
20. Koshkaryev, A., Piroyan, A., & Torchilin, V. P. (2012). Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. *Cancer Biology & Therapy, 13*(1), 50–60.
21. Wang, Y., Ma, X., Su, C., Ma, L., Li, M., & Guo, J. (2013). Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery. *International Journal of Pharmaceutics, 441*(1–2), 748–756.
22. Xie, F., Yao, N., Qin, Y., Zhang, Q., & Yu, J. (2012). Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting. *International Journal of Nanomedicine, 7*, 163–175.
23. Niu, R., Zhang, Y., & Zhang, Y. (2011). Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes. *Journal of Drug Targeting, 19*(5), 373–381.
24. Gupta, Y., Jain, A., & Jain, S. K. (2007). Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. *Journal of Pharmacy and Pharmacology, 59*(7), 935–940.
25. Wang, Z. H., Deng, X., Ding, J., & Wang, J. (2010). Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. *Biomaterials, 31*(33), 908–915.
26. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., & Kumar, D. S. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. *PLoS ONE, 7*(3), e32616.
27. Kurakhmaeva, K. B., et al. (2009). Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. *Journal of Drug Targeting, 17*(8), 564–574.
28. Kafa, H., Wang, J. T.-W., Rubio, N., Venner, K., Anderson, G., & Cassee, F. R. (2015). The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. *Biomaterials, 53*, 437–452.

29. Zhang, Y., et al. (2016). Transporter protein and drug-conjugated gold nanoparticles capable of bypassing the blood-brain barrier. *Scientific Reports, 6*, 25794.
30. Ghalamfarsa, G., et al. (2016). Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis. *Journal of Immunotoxicology, 13*(5), 603–619.
31. Rodrigues, S. F., et al. (2016). Lipid-core nanocapsules act as a drug shuttle through the blood brain barrier and reduce glioblastoma after intravenous or oral administration. *Journal of Biomedical Nanotechnology, 12*(5), 986–1000.
32. Vyas, T. K., Shahiwala, A., & Amiji, M. M. (2008). Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. *International Journal of Pharmaceutics, 347*(1–2), 93–101.
33. Das, D., & Lin, S. (2005). Double-coated poly(butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. *Journal of Pharmaceutical Sciences, 94*(6), 1343–1353.
34. Mittal, G., et al. (2011). Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. *Journal of Controlled Release, 150*(2), 220–228.
35. Mujokoro, B., et al. (2016). Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment: A review. *Materials Science and Engineering: C, 69*, 1092–1102.
36. Chaturbedy, P., et al. (2015). Shape-directed compartmentalized delivery of a nanoparticle-conjugated small-molecule activator of an epigenetic enzyme in the brain. *Journal of Controlled Release, 217*, 151–159.
37. Kreuter, J., et al. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). *Brain Research, 674*(1), 171–174.
38. Gulyaev, A. E., et al. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. *Pharmaceutical Research, 16*(10), 1564–1569.
39. Alyautdin, R. N., et al. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. *Pharmaceutical Research, 14*(3), 325–328.
40. Musumeci, T., et al. (2006). PLA/PLGA nanoparticles for sustained release of docetaxel. *International Journal of Pharmaceutics, 325*(1–2), 172–179.

41. Liu, Y., Sun, J., & Han, J. (2020). Artificial intelligence in drug discovery: Applications and techniques. *Drug Discovery Today, 25*(9), 1576–1584. https://doi.org/10.1016/j.drudis.2020.06.014
42. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery, 17*(2), 97–113. https://doi.org/10.1038/nrd.2017.232
43. Ekins, S., Clark, A. M., Williams, A. J., & Krasowski, M. D. (2012). In silico repositioning of approved drugs for rare and neglected diseases. *Drug Discovery Today, 17*(3–4), 147–152. https://doi.org/10.1016/j.drudis.2011.10.009

44. Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., ... & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. *Nature Reviews Drug Discovery, 18*(1), 41–58. https://doi.org/10.1038/nrd.2018.168
45. Mullard, A. (2020). New drugs cost US$2.6 billion to develop. *Nature Reviews Drug Discovery, 19*(9), 655–655. https://doi.org/10.1038/d41573-020-00165-9
46. Gainetdinov, R. R., Mohn, A. R., & Caron, M. G. (2001). Genetic animal models: Focus on schizophrenia. *Trends in Neurosciences, 24*(9), 527–533. https://doi.org/10.1016/S0166-2236(00)01931-4
47. Winship, I. R., Dursun, S. M., Baker, G. B., Balista, P. A., Kandratavicius, L., Maia-de-Oliveira, J. P., ... & Hallak, J. E. C. (2019). An overview of animal models related to schizophrenia. *Canadian Journal of Psychiatry, 64*(1), 5–17. https://doi.org/10.1177/0706743718773729
48. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics, 47*, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
49. Mak, I. W., Evaniew, N., & Ghert, M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. *American Journal of Translational Research, 6*(2), 114–118.
50. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature Reviews Drug Discovery, 11*(3), 191–200. https://doi.org/10.1038/nrd3681
51. Kapetanovic, I. M. (2008). Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. *Chemico-Biological Interactions, 171*(2), 165–176. https://doi.org/10.1016/j.cbi.2006.12.006
52. Schneider, G., & Fechner, U. (2005). Computer-based de novo design of drug-like molecules. *Nature Reviews Drug Discovery, 4*(8), 649–663. https://doi.org/10.1038/nrd1799
53. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe Jr, E. W. (2014). Computational methods in drug discovery. *Pharmacological Reviews, 66*(1), 334–395. https://doi.org/10.1124/pr.112.007336
54. Pereira, J. C., Caffarena, E. R., & Dos Santos, C. N. (2016). Boosting docking-based virtual screening with deep learning. *Journal of Chemical Information and Modeling, 56*(12), 2495–2506. https://doi.org/10.1021/acs.jcim.6b00355
55. Lo, Y. C., Rensi, S. E., Torng, W., & Altman, R. B. (2018). Machine learning in chemoinformatics and drug discovery. *Drug Discovery Today, 23*(8), 1538–1546. https://doi.org/10.1016/j.drudis.2018.05.010
56. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: Recent advances and future perspectives. *Expert Opinion on Drug Discovery, 16*(8), 949–959. https://doi.org/10.1080/17460441.2021.1924067
57. Ragoza, M., Hochuli, J., Idrobo, E., Sunseri, J., & Koes, D. R. (2017). Protein–ligand scoring with convolutional neural networks. *Journal of Chemical Information and Modeling, 57*(4), 942–957. https://doi.org/10.1021/acs.jcim.6b00740

58. Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. *Journal of Computational Chemistry, 38*(16), 1291–1307. https://doi.org/10.1002/jcc.24764
59. Mater, A. C., & Coote, M. L. (2019). Deep learning in chemistry. *Journal of Chemical Information and Modeling, 59*(6), 2545–2559. https://doi.org/10.1021/acs.jcim.9b00266
60. Altae-Tran, H., Ramsundar, B., Pappu, A. S., & Pande, V. (2017). Low data drug discovery with one-shot learning. *ACS Central Science, 3*(4), 283–293. https://doi.org/10.1021/acscentsci.6b00367
61. Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018). De novo design of bioactive small molecules by artificial intelligence. *Molecular Informatics, 37*(1–2), 1700153. https://doi.org/10.1002/minf.201700153
62. Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., ... & Zholus, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnology, 37*(9), 1038–1040. https://doi.org/10.1038/s41587-019-0224-x
63. Segler, M. H., Preuss, M., & Waller, M. P. (2018). Planning chemical syntheses with deep neural networks and symbolic AI. *Nature, 555*(7698), 604–610. https://doi.org/10.1038/nature25978
64. Gao, W., Coley, C. W., & Jensen, K. F. (2020). The synthesizability of molecules proposed by generative models. *Journal of Chemical Information and Modeling, 60*(12), 5712–5722. https://doi.org/10.1021/acs.jcim.0c00174
65. Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017). druGAN: An advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. *Molecular Pharmaceutics, 14*(9), 3098–3104. https://doi.org/10.1021/acs.molpharmaceut.7b00346
66. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today, 23*(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
67. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 18*(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
68. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., et al. (2020). A deep learning approach to antibiotic discovery. *Cell, 180*(4), 688–702. https://doi.org/10.1016/j.cell.2020.01.021
69. Mamoshina, P., Vieira, A., Putin, E., & Zhavoronkov, A. (2016). Applications of deep learning in biomedicine. *Molecular Pharmaceutics, 13*(5), 1445–1454. https://doi.org/10.1021/acs.molpharmaceut.5b00982
70. Walters, W. P., Murcko, M., & Murcko, M. A. (2020). Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnology, 38*(2), 143–145. https://doi.org/10.1038/s41587-019-0396-1
71. Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019). Exploiting machine learning for end-to-end drug discovery and

development. *Nature Materials, 18*(5), 435–441. https://doi.org/10.1038/s41563-019-0338-0

72. Lavecchia, A. (2019). Deep learning in drug discovery: Opportunities, challenges and future prospects. *Drug Discovery Today, 24*(10), 2017–2032. https://doi.org/10.1016/j.drudis.2019.05.018
73. Walters, W. P., Murcko, M., & Murcko, M. A. (2020). Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnology, 38*(2), 143–145. https://doi.org/10.1038/s41587-019-0396-1
74. Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019). Deep learning for molecular design—a review of the state of the art. *Molecular Systems Design & Engineering, 4*(5), 828–849. https://doi.org/10.1039/C9ME00039A
75. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today, 23*(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
76. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., et al. (2020). A deep learning approach to antibiotic discovery. *Cell, 180*(4), 688–702. https://doi.org/10.1016/j.cell.2020.01.021
77. Mamoshina, P., Vieira, A., Putin, E., & Zhavoronkov, A. (2016). Applications of deep learning in biomedicine. *Molecular Pharmaceutics, 13*(5), 1445–1454. https://doi.org/10.1021/acs.molpharmaceut.5b00982
78. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery, 17*(2), 97–113. https://doi.org/10.1038/nrd.2017.232
79. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today, 23*(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
80. Walters, W. P., Murcko, M., & Murcko, M. A. (2020). Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnology, 38*(2), 143–145. https://doi.org/10.1038/s41587-019-0396-1